GB9123326D0 - Improvements in or relating to organic compounds - Google Patents

Improvements in or relating to organic compounds

Info

Publication number
GB9123326D0
GB9123326D0 GB919123326A GB9123326A GB9123326D0 GB 9123326 D0 GB9123326 D0 GB 9123326D0 GB 919123326 A GB919123326 A GB 919123326A GB 9123326 A GB9123326 A GB 9123326A GB 9123326 D0 GB9123326 D0 GB 9123326D0
Authority
GB
United Kingdom
Prior art keywords
relating
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB919123326A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Priority to GB919123326A priority Critical patent/GB9123326D0/en
Publication of GB9123326D0 publication Critical patent/GB9123326D0/en
Priority to PCT/EP1992/002472 priority patent/WO1993009135A1/en
Priority to JP5508146A priority patent/JPH07500828A/en
Priority to HU9401303A priority patent/HUT68200A/en
Priority to SK511-94A priority patent/SK51194A3/en
Priority to CZ941067A priority patent/CZ106794A3/en
Priority to CA002116653A priority patent/CA2116653A1/en
Priority to EP92922580A priority patent/EP0611375A1/en
Priority to AU28852/92A priority patent/AU2885292A/en
Priority to NZ244985A priority patent/NZ244985A/en
Priority to PT101027A priority patent/PT101027A/en
Priority to IL103612A priority patent/IL103612A0/en
Priority to MX9206306A priority patent/MX9206306A/en
Priority to ZA928511A priority patent/ZA928511B/en
Priority to NO941629A priority patent/NO941629L/en
Priority to FI942061A priority patent/FI942061A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
GB919123326A 1991-11-04 1991-11-04 Improvements in or relating to organic compounds Pending GB9123326D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GB919123326A GB9123326D0 (en) 1991-11-04 1991-11-04 Improvements in or relating to organic compounds
JP5508146A JPH07500828A (en) 1991-11-04 1992-10-29 Peptides that inhibit IL-1β release
CA002116653A CA2116653A1 (en) 1991-11-04 1992-10-29 Peptides inhibiting il-1 beta release
AU28852/92A AU2885292A (en) 1991-11-04 1992-10-29 Peptides inhibiting il-1 beta release
HU9401303A HUT68200A (en) 1991-11-04 1992-10-29 Process for producing peptides inhibiting il-1-beta release and pharmaceutical compositions containing them as active component
SK511-94A SK51194A3 (en) 1991-11-04 1992-10-29 Peptides
CZ941067A CZ106794A3 (en) 1991-11-04 1992-10-29 Peptides
PCT/EP1992/002472 WO1993009135A1 (en) 1991-11-04 1992-10-29 Peptides inhibiting il-1 beta release
EP92922580A EP0611375A1 (en) 1991-11-04 1992-10-29 Peptides inhibiting il-1 beta release
NZ244985A NZ244985A (en) 1991-11-04 1992-11-02 Peptide compounds, preparation and pharmaceutical compositions thereof
IL103612A IL103612A0 (en) 1991-11-04 1992-11-02 Peptides,their preparation and pharmaceutical compositions containing them
PT101027A PT101027A (en) 1991-11-04 1992-11-02 Process for their preparation and their use as pharmaceutical compositions
MX9206306A MX9206306A (en) 1991-11-04 1992-11-03 PEPTIDES, PROCEDURE FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM.
ZA928511A ZA928511B (en) 1991-11-04 1992-11-04 Peptides
NO941629A NO941629L (en) 1991-11-04 1994-05-03 Peptides that inhibit 1L-1
FI942061A FI942061A (en) 1991-11-04 1994-05-04 IL-1 beta inhibitory peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919123326A GB9123326D0 (en) 1991-11-04 1991-11-04 Improvements in or relating to organic compounds

Publications (1)

Publication Number Publication Date
GB9123326D0 true GB9123326D0 (en) 1991-12-18

Family

ID=10703998

Family Applications (1)

Application Number Title Priority Date Filing Date
GB919123326A Pending GB9123326D0 (en) 1991-11-04 1991-11-04 Improvements in or relating to organic compounds

Country Status (16)

Country Link
EP (1) EP0611375A1 (en)
JP (1) JPH07500828A (en)
AU (1) AU2885292A (en)
CA (1) CA2116653A1 (en)
CZ (1) CZ106794A3 (en)
FI (1) FI942061A (en)
GB (1) GB9123326D0 (en)
HU (1) HUT68200A (en)
IL (1) IL103612A0 (en)
MX (1) MX9206306A (en)
NO (1) NO941629L (en)
NZ (1) NZ244985A (en)
PT (1) PT101027A (en)
SK (1) SK51194A3 (en)
WO (1) WO1993009135A1 (en)
ZA (1) ZA928511B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
EP0519748B1 (en) * 1991-06-21 1998-09-02 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
ES2118940T3 (en) * 1992-02-21 1998-10-01 Merck & Co Inc PEPTIDIL-DERIVATIVES USEFUL AS INHIBITORS OF THE CONVERTING ENZYME OF INTERLEUKIN-1 BETA.
EP0618223A3 (en) * 1993-03-08 1996-06-12 Sandoz Ltd Peptides inhibiting interleukin 1-bêta release useful as antiinflammatory agents.
US5985838A (en) 1993-04-29 1999-11-16 Vertex Pharmaceuticals, Inc. Peptide analogs as irreversible interleukin-1β protease inhibitors
CA2122227A1 (en) * 1993-04-29 1994-10-30 Roland E. Dolle Peptide analogs as irreversible interleukin-1.beta. protease inhibitors
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (en) * 1993-06-03 1995-04-04 Sterling Winthrop Inc Interleukin-1 beta transfer enzyme inhibitor
EP0644197B1 (en) * 1993-06-04 1998-09-09 Vertex Pharmaceuticals Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
AU7714594A (en) * 1993-08-13 1995-03-14 Merck & Co., Inc. Substituted ketone derivatives as inhibitors of interleukin-1beta converting enzyme
US5714484A (en) * 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5565430A (en) * 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
GB2292149A (en) * 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
WO1996030395A2 (en) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5798442A (en) * 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
EP0761680A3 (en) * 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6136834A (en) * 1995-12-27 2000-10-24 Ono Pharmaceutical Co., Ltd. Tetrazole compounds and pharmaceutical agents containing such derivative
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5968927A (en) 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
WO1998037880A1 (en) * 1997-02-26 1998-09-03 Ciblex Corporation Inhibitors of leaderless protein export
US6306613B1 (en) 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
DE69925581T2 (en) 1998-03-09 2006-04-27 Vertex Pharmaceuticals Inc., Cambridge 1,2-DIAZEPANDERIVATE AS INHIBITORS OF INTERLEUKIN-1BETA CONVERTING ENZYME
NZ528282A (en) 1998-03-19 2005-05-27 Vertex Pharma Interleukin-1 beta converting enzyme inhibitors
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
KR20020005665A (en) * 1999-04-09 2002-01-17 추후보정 Caspase inhibitors and the use thereof
US6525024B1 (en) 2000-04-17 2003-02-25 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
EP2241328A1 (en) 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
PE20011350A1 (en) 2000-05-19 2002-01-15 Vertex Pharma PROPHARMAC OF AN INHIBITOR OF INTERLEUKIN-1ß CONVERTER ENZYME (ICE)
US6800619B2 (en) * 2000-09-13 2004-10-05 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2003075853A2 (en) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
PT2399916E (en) 2004-03-12 2015-03-17 Vertex Pharma Process and intermediates for the preparation of aspartic acetal caspase ihnhibitors
US7531570B2 (en) 2004-05-27 2009-05-12 Vertex Pharmaceuticals Incorporated Treatment of diseases using ICE inhibitors
CN101979403A (en) * 2010-09-13 2011-02-23 沈陵陵 Novel broad caspase inhibitor and preparation method and application thereof
WO2012061786A1 (en) 2010-11-05 2012-05-10 Brandeis University Ice cleaved alpha-synuclein a biomarker
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
BR112018009511A2 (en) 2015-11-13 2018-11-06 Novartis Ag pyrazolo pyrimidine derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015577A1 (en) * 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE

Also Published As

Publication number Publication date
FI942061A0 (en) 1994-05-04
HU9401303D0 (en) 1994-08-29
HUT68200A (en) 1995-05-29
AU2885292A (en) 1993-06-07
CZ106794A3 (en) 1994-12-15
WO1993009135A1 (en) 1993-05-13
NO941629L (en) 1994-07-04
PT101027A (en) 1994-02-28
NO941629D0 (en) 1994-05-03
IL103612A0 (en) 1993-04-04
CA2116653A1 (en) 1993-05-13
JPH07500828A (en) 1995-01-26
FI942061A (en) 1994-05-04
SK51194A3 (en) 1995-02-08
NZ244985A (en) 1995-06-27
ZA928511B (en) 1994-05-04
MX9206306A (en) 1993-05-01
EP0611375A1 (en) 1994-08-24

Similar Documents

Publication Publication Date Title
GB9123326D0 (en) Improvements in or relating to organic compounds
GB9105705D0 (en) Improvements in or relating to organic compounds
GB9107196D0 (en) Improvements in or relating to organic compounds
GB9108135D0 (en) Improvements in or relating to organic compounds
GB9110544D0 (en) Improvements in or relating to organic compounds
GB9102450D0 (en) Improvements in or relating to organic compounds
GB9110679D0 (en) Improvements in or relating to organic compounds
GB9106179D0 (en) Improvements in or relating to organic compounds
GB9106104D0 (en) Improvements in or relating to organic compounds
GB9105930D0 (en) Improvements in or relating to organic compounds
GB9109197D0 (en) Improvements in or relating to organic compounds
GB9109177D0 (en) Improvements in or relating to organic compounds
GB9108965D0 (en) Improvements in or relating to organic compounds
GB9108855D0 (en) Improvements in or relating to organic compounds
GB9107927D0 (en) Improvements in or relating to organic compounds
GB9107926D0 (en) Improvements in or relating to organic compounds
GB9107925D0 (en) Improvements in or relating to organic compounds
GB9107924D0 (en) Improvements in or relating to organic compounds
GB9107918D0 (en) Improvements in or relating to organic compounds
GB9107623D0 (en) Improvements in or relating to organic compounds
GB9107308D0 (en) Improvements in or relating to organic compounds
GB9107295D0 (en) Improvements in or relating to organic compounds
GB9107197D0 (en) Improvements in or relating to organic compounds
GB9106668D0 (en) Improvements in or relating to organic compounds
GB9110693D0 (en) Improvements in or relating to organic compounds